Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +24.42%
#3 Ankr Network Ankr Network +21.29%
#4 BankrCoin BankrCoin +18.65%
#5 Status Status +13.53%
#6 Pons Pons +9.90%
#7 Provenance Blockchain Provenance Blockchain +9.18%
#8 Hive Hive +8.50%
#9 Useless Coin Useless Coin +8.27%
#10 Wrapped Aave Ethereum WETH Wrapped Aave Ethereum WETH +7.84%
Coin of the day
Palladium Network Palladium Network
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Orchard Therapeutics plc Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
Classificação em ações #18160
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing... Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Preço da ação
$16.70
Última sincronização: 2024-02-02
Valor de mercado
$210.34M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
GB
Negociar Orchard Therapeutics plc (ORTX)

Categoria

Healthcare
Rácio P/S de Orchard Therapeutics plc (ORTX)
Rácio P/S em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Orchard Therapeutics plc, o rácio P/S atual (TTM) é 0. No final de 2026, o rácio P/S era 0.
Histórico do rácio P/S da Orchard Therapeutics plc de 2026 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
Não há dados suficientes para as datas fornecidas.
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.95 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.19 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
24.99 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.75 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH